Design, synthesis, and antibacterial assessment of a new series of ciprofloxacin-based compounds as possible dual DNA gyrase/topoisomerase IV inhibitors.

Lamya H Al-Wahaibi, Hayat Ali Alzahrani, Stefan Bräse, Bahaa G M Youssif, Mohamed Hisham

Abstract read

In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Lamya H Al-WahaibiDepartment of Chemistry, College of Sciences, Princess Nourah bint Abdulrahman University, Riyadh, 11671, Saudi Arabia.

Hayat Ali AlzahraniMedical Laboratory Technology Department, Applied Medical Science College, Northern Border University, Arar, Saudi Arabia.

Stefan BräseInstitute of Biological and Chemical Systems, IBCS-FMS, Karlsruhe Institute of Technology, 76131, Karlsruhe, Germany. braese@kit.edu.

Bahaa G M YoussifPharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Assiut University, Assiut, 71526, Egypt. bgyoussif2@gmail.com.

Mohamed HishamPharmaceutical Chemistry Department, Faculty of Pharmacy, Deraya University, Minia, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Simultaneous inhibition of DNA gyrase and topoisomerase IV (Topo IV) is a primary pharmacological strategy to enhance antibacterial efficacy and markedly reduce the emergence of antibiotic resistance. In this regard, a new set of twelve ciprofloxacin-based derivatives was rationally developed, synthesized, and structurally verified. The DNA gyrase and Topo IV inhibitory actions of the developed Compounds 6a-l were investigated. Compound 6 g showed the most promising results, with IC

Indexed as

Anti-Bacterial AgentsCiprofloxacinDNA GyraseDNA Topoisomerase IVDrug DesignTopoisomerase II InhibitorsBiofilmsEscherichia coliMicrobial Sensitivity TestsMolecular Docking SimulationPseudomonas aeruginosaStaphylococcus aureusStructure-Activity RelationshipAnti-Bacterial AgentsCiprofloxacinDNA GyraseDNA Topoisomerase IVTopoisomerase II InhibitorsAnti-biofilmBacterial resistanceCiprofloxacinDNA gyraseFluoroquinoloneTopo IV

Identifiers

PMID42062392

DOI10.1038/s41598-026-50106-z

PMCPMC13133380

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.